<DOC>
	<DOCNO>NCT02205372</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics MT-3995 Subjects Diabetic Nephropathy .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study MT-3995 Low Dose Subjects With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Subjects Type 2 diabetes mellitus diabetic nephropathy , treat stable dose angiotensin convert enzymeinhibitor ( ACEI ) angiotensin II receptor blocker ( ARB ) Glycosylated haemoglobin ( HbA1c ) â‰¤10.5 % Subject albuminuria Subjects type 1 diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus ( Cushing 's syndrome , steroidogenic diabetes ) . Serum potassium level &lt; 3.5 &gt; 5.0 mmol/L Subjects acute kidney injury within 3 month prior baseline undergone hemodialysis time prior randomisation Subjects clinically significant hypotension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>